Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these applications open the possibility for CYBN to obtain patent coverage in 153 countries and, if approved, allow the company to file future national applications into treaty member jurisdictions. The company filed the applications under … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files Two International Patent Applications in Support of the Company’s Research Phase Programs”
Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed a nonprovisional patent application in support of its ongoing drug candidate programs. The company noted that it had completed a favorable international search report regarding its May 2021 Patent Cooperation Treaty (“PCT”) application; as a result, it filed the U.S. … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files 14th Patent Application, Announces New Board Member”
Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced its unaudited business highlights and financial results for the three-month period ended June 30, 2021. In the report, the company noted it had become the first psychedelic company to list on the NYSE American LLC stock exchange, a milestone reached on … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Financial, Business Results”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has noted key achievements reached by its wholly owned subsidiary Adelia Therapeutics Inc. Most notably, Adelia has achieved key milestones outlined in the terms of a contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders. Those … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Q1 Milestones for Subsidiary — Notes Corrected Information”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has noted key achievements reached by its wholly owned subsidiary Adelia Therapeutics Inc. Most notably, Adelia has achieved key milestones outlined in the terms of a contribution agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous Adelia shareholders. Consequently, … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Q1 Milestones for Subsidiary”
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has signed agreements with both Calvert Labs and Gad Consulting Services to design, execute and collaborate on exploratory studies related to Tryp’s Psilocybin-for-Neuropsychiatric Disorders, or PFN(TM) (“PFN”), program. An Altasciences company, Calvert Labs … Continue reading “NetworkNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnerships to Explore, Develop Proprietary Psilocybin Formulations”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in Canaccord Genuity’s 41st annual growth conference. Company CEO Doug Drysdale will be presenting at the conference, which will be held virtually on Aug. 10, 2021. According to the announcement, the presentation will begin at 3:30 p.m. ET … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in Upcoming 41st Annual Canaccord Genuity Growth Conference”
Company announces official approval for its common shares to be listed, traded on NYSE American Cybin will commit resources to reach the broadest investor audience, accelerate efforts to position Cybin as sector leader Companies that list on NYSE American can leverage a wide range of advantages In an historic move, Cybin (NEO: CYBN) (NYSE American: … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Marks Milestone Moment as First Psychedelic Biotech to Trade on NYSE American Exchange”
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has announced that on trading opens on Aug. 5, 2021, its common shares will be trading on the NYSE American LLC stock exchange; the shares will trade under the symbol CYBN. According to the announcement, Cybin’s common shares will also continue to … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Begin Trading on NYSE American”
Related Editorial In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords biotechnology and pharmaceutical companies an expedited review process for experimental drugs that may have treatment advantages over existing therapies for hard-to-treat diseases. In November 2013, Gazyva, a drug used in combination with chlorambucil for patients with chronic … Continue reading “NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Breaks New Ground in Psilocybin Space”
